Altimmune (ALT) Stock Price, News & Analysis

Company Overview

Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose. This candidate is being advanced in collaboration with the University of Alabama at Birmingham and is supported by the National Institute of Allergy and Infectious Diseases. In parallel, Altimmune’s HepTcell program aims to treat chronic hepatitis B by eliciting targeted T-cell responses capable of clearing infected liver cells.

Altimmune’s AdCOVID™ platform uses a replication-incompetent adenovirus vector to deliver vaccine antigens directly to the nasal mucosa, and it is also under evaluation for additional respiratory pathogens, including coronaviruses. The company maintains a pipeline of preclinical programs in liver and metabolic diseases, reflecting its commitment to harnessing immunotherapy and vaccine design across multiple therapeutic areas.

The company’s leadership team combines extensive scientific expertise and operational experience in vaccine research and development. Through a strategic blend of translational science and external partnerships, Altimmune seeks to advance innovative therapies that improve patient outcomes and address global health challenges.

Key Stats

• Today's Range: $3.86 to $4.06
• 50-Day Range: $3.39 to $4.01
• 52-Week Range: $2.90 to $11.16
• Volume: 3.01 million shs
• Average Volume: 2.81 million shs
• Market Capitalization: $353.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.40
• Consensus Rating: Hold

Altimmune Stock Analysis - MarketRank™

Altimmune scored higher than 45% of companies evaluated by MarketBeat, and ranked 586th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Altimmune has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Altimmune has a consensus price target of $17.40, representing about 335.0% upside from its current price of $4.00.

Amount of Analyst Coverage

Altimmune has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Altimmune are expected to grow in the coming year, from ($1.35) to ($0.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Altimmune is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Altimmune is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Altimmune has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.67% of the outstanding shares of Altimmune have been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Altimmune has recently increased by 4.43%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Altimmune does not currently pay a dividend.

Dividend Growth

Altimmune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.67% of the outstanding shares of Altimmune have been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Altimmune has recently increased by 4.43%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.49

News Sentiment

Altimmune has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Altimmune this week, compared to 9 articles on an average week.

Search Interest

Only 50 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

4 people have added Altimmune to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Altimmune insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.40% of the stock of Altimmune is held by insiders.

Percentage Held by Institutions

78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALT Stock Analysis - Frequently Asked Questions

How have ALT shares performed this year?

Altimmune's stock was trading at $7.21 at the beginning of the year. Since then, ALT stock has decreased by 44.5% and is now trading at $4.00.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.05. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0 million. Altimmune had a negative net margin of 438,730.03% and a negative trailing twelve-month return on equity of 62.63%.
Read the conference call transcript.

When did Altimmune's stock split?

Shares of Altimmune reverse split on the morning of Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Altimmune's major shareholders?

Altimmune's top institutional shareholders include Summit Financial Wealth Advisors LLC (0.11%) and Voya Investment Management LLC (0.02%). Insiders that own company stock include David Drutz, Matthew Scott Harris, Gregory L Weaver and Wayne Pisano.
View institutional ownership trends.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/21/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALT
• CIK: 1326190
• Web: altimmune.com
• Phone: (240) 654-1450
• Fax: 410-269-2601
• Employees: 50
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Altimmune: $17.40
• High Price Target: $24.00
• Low Price Target: $12.00
• Potential Upside/Downside: +335.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.06 million
• Net Margins: -438,730.03%
• Pretax Margin: -442,135.00%
• Return on Equity: -62.63%
• Return on Assets: -55.29%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 20.44
• Quick Ratio: 20.44

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 17,652.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 88,260,000
• Free Float: 84,374,000
• Market Cap: $353.04 million
• Optionable: Optionable
• Beta: 0.07